Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2021
April 14, 2021 at 10:21 pm
Share
Cryo-Cell International, Inc. announced earnings results for the first quarter ended February 28, 2021. For the first quarter, the company announced total revenue was USD 6.860 million compared to USD 7.620 million a year ago. Operating income was USD 1.235 million compared to USD 1.249 million a year ago. Net income was USD 693,590 compared to USD 686,966 a year ago. Basic earnings per share from continuing operations was USD 0.09 compared to USD 0.09 a year ago. Diluted earnings per share from continuing operations was USD 0.08 compared to USD 0.08 a year ago.
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
CRYO-CELL INTERNATIONAL, INC. 
